Previous | Home | EndoTODAY | List | Next
[Tachycardia due to cimetropium (Algiron)]
50´ë alcoholicsÀÇ ³»½Ã°æÀ» À§ÇÏ¿© cimetropiumÀ» Åõ¿©ÇÏ°í ¼öºÐ ÈÄ ºó¸ÆÀÌ ¹ß»ýÇÏ¿´½À´Ï´Ù. ¾ÆÁÖ µå¹® ÀÏÀÔ´Ï´Ù¸¸... ¾Ë°í °è½Ã¸é ÁÁ°Ú½À´Ï´Ù.
Àü¹®°¡¿¡°Ô ¹®ÀÇÇÏ¿© ¾Æ·¡¿Í °°Àº ´äº¯À» ¹Þ¾Ò½À´Ï´Ù.
¹®ÀÇÇϽŠcimetropium (¾Ë±â·Ð ÁÖ»ç 5mg/ml) °ü·ÃÇÑ ³»¿ëÀÔ´Ï´Ù. CimetropiumÀÇ Á¦Ç° Çã°¡»çÇ׿¡ ÀÇÇϸé "°í¿ë·® »ç¿ëÇÒ ¶§ ½ÃÁ¶ÀýÀå¾Ö, ºó¸ÆÀ» µ¿¹ÝÇÑ ½É°èÇ×Áø, °¨°¢ Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù" °í ±âÀçµÇ¾î ÀÖ½À´Ï´Ù.
CimetropiumÀÇ °æ¿ì ¹Ì±¹ Çã°¡ÀǾàÇ°ÀÌ ¾Æ´Ï¶ó¼ CCIS µî °Ë»ö°¡´ÉÇÑ ÀÚ·á°¡ Á¦ÇÑÀûÀ̸ç, ½Å¾à½ÉÀǽà Á¦¾àȸ»ç¿¡¼ Á¦ÃâÇÑ DC¹®ÇåÁý¿¡ ¼ö·ÏµÈ ³í¹®À» »ìÆ캻 °á°ú, ÀϽÃÀûÀÎ ºó¸Æ, ¶Ç´Â ÁÖ°üÀûÀÎ ºó¸Æ, ¶Ç´Â ºó¸Æ ¹ß»ýÀÌ ¾ð±ÞµÈ ¹Ù ÀÖ½À´Ï´Ù. PSVT µî ±¸Ã¼ÀûÀÎ Á¾·ùÀÇ ºó¸Æ¿¡ ´ëÇØ ¾ð±ÞµÈ ÀÚ·á´Â ¾ø¾ú½À´Ï´Ù. ¾Æ·¡´Â Âü°í ¹®Çå ³»¿ëÀÔ´Ï´Ù.
1) Cimetropium bromide as a relaxant for the radiological examination of the stomach and duodenum.
- 28-74¼¼ÀÇ ³²ÀÚ 22¸í, ¿©ÀÚ 18¸í (ÃÑ 40¸í) ´ë»ó
- cimetropium 5 mg or 10 mg Åõ¿©
- ºÎÀÛ¿ë ´ëºÎºÐÀÇ È¯ÀÚµéÀÌ Åõ¿© ÈÄ ÀϽÃÀûÀÎ ºó¸ÆÁõ»óÀ» ³ªÅ¸³»¾úÀ½ (up to 120 beats per minutes)2) Efficacy of cimetropium bromide as pre-medication for double-contrast barium enema
- cimetropium 5 mg Åõ¿©±º Áß 4%¿¡¼ tachycarida ¹ß»ý,
- cimetropium 10 mg Åõ¿©±º Áß 7%¿¡¼ tachycardia ¹ß»ý3) »õ·Î¿î ¹°Áú alginron ÀÇ Áø°æÀÛ¿ë¿¡ ´ëÇÑ ¿¬±¸ (La Clinica Terapeutica. 1977 vol. 83. Fasc. 6, page 609-623)
- ±ÙÀ°³» Åõ¿©½Ã ÀÓ»óÀûÀÎ Àǹ̰¡ ¾ø´Â Á¤µµÀÇ ÀáÁ¤ÀûÀÎ ½É°èÇ×ÁøÀ» À¯¹ß½ÃÅ´
- 5 mg Á¤¸Æ³» Åõ¿©ÇÑ 17 ¸í Áß 2¸í¿¡¼ ¾à 5ºÐÁ¤µµÀÇ Áö¼Ó±â°£µ¿¾È °¡º¿î ½É°èÇ×ÁøÀÇ ´À³¦À» Çϼҿ¬ÇÔ. (´ëÁ¶±º scopolamineÀÇ °æ¿ì 17¸í Áß 5¸í ¹ß»ý,
- ½É¹Ú¼öÀÇ Áõ°¡´Â Á¤»ó¹üÀ§ ³»¿¡ ÀÖ´Â °ÍÀ¸·Î Áõ¸íµÇ¾ú°í, ÁÖ°üÀûÀÎ Áõ»ó È£¼Ò¿´À½.)
- ¾Ë±â·Ð Åõ¿© ÈÄ ¹ß»ýÇÑ ½É°èÇ×ÁøÀº ºÎÀÛ¿ëÀ̶ó±â º¸´Ù´Â Ç×Äݸ°¼º È¿´ÉÀÌ ÀÖ´Â ¸ðµç Áø°æÁ¦µéÀÇ ÀϹÝÀûÀÌ°í Ư¡ÀûÀÎ Çö»óÀ¸·Î ÆǴܵÊ.
¿À´Ã Àú³á ÇÑ È¸»ç ÁÖ°üÀÇ GERD symposiumÀÌ ÀÖ½À´Ï´Ù. ¸¶Áö¸· °ÀÇ´Â Á¦°¡ ÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
°ÀÇ ³»¿ëÀÌ ±â»ç·Î ¿ä¾àµÇ¾ú½À´Ï´Ù.
1. ÃÖ±Ù 20³â »çÀÌ ¿ì¸®³ª¶ó GERDÀÇ À¯º´·üÀº ²ÙÁØÈ÷ Áõ°¡ÇÏ¿´½À´Ï´Ù. ±×·¯³ª ¾ÕÀ¸·Î °è¼Ó Áõ°¡ÇÒ °ÍÀÎÁö, ¾Æ´Ï¸é ÀÏÁ¤ ¼öÁØ¿¡¼ plateau¸¦ Çü¼ºÇÒÁö´Â ¹ÌÁö¼öÀÔ´Ï´Ù. Àú´Â Áõ°¡Ãß¼¼°¡ ´ÊÃß¾îÁú °ÍÀ¸·Î º¾´Ï´Ù.
2. Hiatal hernia´Â Áß¿äÇÑ ÁúȯÀÓ¿¡µµ ºÒ±¸ÇÏ°í Áø´ÜÀÌ ¾Ö¸ÅÇÏ´Ù´Â ÀÌÀ¯·Î ¹«½Ã´çÇÏ°í ÀÖ´Â ºÒ½ÖÇÑ ÁúȯÀÔ´Ï´Ù. Hiatal hernia°¡ Àִ ȯÀÚ¿¡¼ LA group DÀÇ ½ÉÇÑ ¿ª·ù¼º ½Äµµ¿°ÀÌ ¸¹½À´Ï´Ù. Strictureµµ Àß µ¿¹ÝµË´Ï´Ù. ÀÓ»óÀû ÀÇÀÇ¿¡ ´ëÇÏ¿© ³í¶õÀÌ ¸¹Áö¸¸ Àú´Â ¾Æ·¡¿Í °°ÀÌ º¸°í ÀÖ½À´Ï´Ù.
i) ¹«Áõ»ó ¼ºÀο¡¼ ¹ß°ßµÇ´Â °æÁõÀÇ hiatal hernia¿¡´Â ÀÓ»óÀû ÀÇÀǸ¦ ºÎ¿©ÇÏÁö ¾Ê´Â´Ù.
ii) ¹«Áõ»ó ¼ºÀο¡¼ ¹ß°ßµÇ´Â ½ÉÇÑ hiatal hernia´Â ȯÀÚ¿¡°Ô ½ÄµµÁõ»ó ¿©ºÎ¸¦ ¹°¾îº¸¶ó´Â sign Á¤µµ·Î °£ÁÖÇÑ´Ù.
iii) À§½Äµµ ¿ª·ùÁõ»óÀÌ Àִ ȯÀÚ¿¡¼ mucosal break¸¦ µ¿¹ÝÇÑ hiatal hernia´Â ½ÉÇÑ GERDÀÇ signÀÏ ¼ö ÀÖ´Ù.
iv) À§½Äµµ ¿ª·ùÁõ»óÀÌ Àִ ȯÀÚ¿¡¼ mucosal break¸¦ µ¿¹ÝÇÏÁö ¾ÊÀº hiatal hernia´Â ºñ·Ï erosive esophagitis¶ó°í Áø´ÜÇÒ ¼ö ¾ø´õ¶óµµ GERDÀÇ ÀÓ»óÁø´ÜÀ» supportÇÏ´Â °£Á¢ÀûÀÎ ¼Ò°ßÀ¸·Î °£ÁÖÇÑ´Ù.
3. À§½Äµµ¿ª·ùÁúȯÀÇ ³»½Ã°æÁø´Ü¿¡´Â ÀûÁö ¾ÊÀº °üÂûÀÚ°£ Â÷ÀÌ°¡ ÀÖ½À´Ï´Ù. ¾ÆÁÖ µå¹°°Ô EG junctionÀÇ ¾Ï°ú ¿ª·ù¼º ½Äµµ¿°À» È¥µ¿ÇÒ ¼ö ÀÖÀ¸´Ï high index of suspicionÀ» °¡Áú ÇÊ¿ä°¡ ÀÖ½À´Ï´Ù.
4. À§½Äµµ¿ª·ùÁúȯ Ä¡·áÀÇ ±Ù°£Àº PPIÀÔ´Ï´Ù. PPI´Â H2RA º¸´Ù Áõ»ó ¿ÏÈ ¼Óµµ¿Í ½Äµµ¿° Ä¡À¯ ¼Óµµ°¡ 2¹è Á¤µµ ºü¸¨´Ï´Ù. »ç½Ç º¸ÅëÀÇ °æ¿ì H2RA¸¦ »ç¿ëÇÒ ÀÌÀ¯°¡ º°·Î ¾ø½À´Ï´Ù.
5. On demand therapy¸¦ »ç¿ëÇϸé esophageal erosionÀ» ¿Ïº®È÷ Ä¡·áÇÏÁö ¸øÇÏ´õ¶óµµ ȯÀÚ´Â Áõ»ó¾øÀÌ ÇູÇÏ°Ô Áö³¾ ¼ö ÀÖ½À´Ï´Ù. ¾àÀ» Àû°Ô »ç¿ëÇÒ ¼ö ÀÖÀ¸´Ï ¹«Ã´ ÁÁÀº ¹æ¹ýÀÔ´Ï´Ù (»ç½Ç Àú´Â threshold therapy°¡ ÈξÀ ´õ ÁÁ´Ù°í »ý°¢ÇÕ´Ï´Ù. ¼Ò¼ö ÀÇ°ßÀÎÁö¶ó ´ë³õ°í ¶°µéÁö ¸øÇÒ »ÓÀÔ´Ï´Ù. ÀÓ»ó °æÇè¿¡ ºñÃß¾î º¸¸é È®½ÇÇÕ´Ï´Ù.). ȯÀÚ´Â ³»½Ã°æ ¼Ò°ßÀÌ ÁÁ¾ÆÁ³´ÂÁö °ü½ÉÀÌ ¸¹½À´Ï´Ù. ÀÇ»ç´Â ±×·¯¸é ¾ÈµË´Ï´Ù. ȯÀÚÀÇ Áõ»óÀÌ ÁÁ¾ÆÁ³´ÂÁö °ü½ÉÀ» °¡Á®¾ß ÇÕ´Ï´Ù. On demand therapy´Â ¾Æ·¡¿Í °°ÀÌ ÇÏ´Â °ÍÀÔ´Ï´Ù (Bour B. APT 2005;21:805).
i) The recurrence of your determining symptom at a level which you judge as incompatible with your well-being should lead to the start of the treatment.
ii) The disappearance of this symptom for 48 h should lead to discontinuation of the treatment.
6. Àú´Â every other day·Î Åõ¾àÇÏ´Â °ÍÀ» ÁÁ¾ÆÇÕ´Ï´Ù. Threshold therapy¿¡ °¡±õ½À´Ï´Ù. Threshold therapy´Â ¾Æ·¡¿Í °°ÀÌ ÇÏ´Â °ÍÀÔ´Ï´Ù (Zancy. Aliment Pharmacol Ther 2005;21:1299-312).
i) For 'threshold' therapy, patients gradually increase the interval between medications (for example, to every second or third day) as long as symptoms do not recur.
ii) The patient titrates the medication down to a frequency that still maintains adequate control of symptoms.
iii)This is different from on-demand therapy where each time the patient waits for recurrence of symptoms.
1) ±â´É¼º,¿îµ¿Áúȯ ÇмúÇà»ç on-line Áß°è
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng